Compare EchoStar Corporation Common Stock (ECHO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EchoStar Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? EchoStar Corporation Common Stock trades at $96.54 (market cap $28.41B), while Summit Therapeutics Inc trades at $17.27 (market cap $14.33B). The key difference: EchoStar Corporation Common Stock is the larger of the two by market cap, and Summit Therapeutics Inc is more actively traded (8,167,213 versus 3,258,295). Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 0 Days and Summit Therapeutics Inc for 16 Days on average.
| ECHO | SMMT | |
|---|---|---|
Market Cap | $28.41B | $14.33B |
Volume | 3,258,295 | 8,167,213 |
Sector | Media | Health |
52-Week High | $141.80 | $26.38 |
52-Week Low | $66.93 | $12.43 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $45.47B | $13.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EchoStar Corporation Common Stock
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
